Abstract:Objective To study programmed death-1 (PD-1) and T-cell immunoglobulin mucin3 (Tim-3) co-expression on peripheral blood mononuclear cells (PBMC) and hepatitis B virus (HBV)-specific CD8+ T cells in patients with chronic HBV infection and its correlation with liver inflammatory activities.Methods One hundred and sixty subjects with chronic HBV infection who visited the outpatient and inpatient Department of Infectious Diseases in the Third Affiliated Hospital of Sun Yatsen University were enrolled,including 63 cases of mild or moderate CHB (MCHB),31 of severe CHB (SCHB),55 of acute-on-chronic liver failure (ACLF) and 11 inactive HBsAg carriers.Twenty healthy subjects were enrolled as controls.Real-time quantitative polymerase chain reaction (qRT-PCR) was used to detect HBV DNA,enzyme-linked immunosorbent assay (ELISA) to measure HBV serological markers,and flow cytometry to detect human leukocyte antigen (HLA)-A2 and determine the expression of PD-1 and Tim-3 on PBMC and HBV-specific CD8+ T cells.Cell counts of Tim-3+,PD-1+,and Tim-3+/PD1+ PBMC and HBV-specific CD8+ T cells were compared among different groups,and their correlation with commonly used inflammatory activity indicators were studied.Analysis of variance and Kruskal-Wallis test were used for measurement data with gaussian distribution and skewed distribution,respectively.Spearman correlation analysis was used to assess the association between Tim-3/PD-1 expression and inflammatory activity indicators.Results The frequency of Tim-3+/PD-1+ PBMC was 0.25 ％ in ACLF group (P=0.0049),0.24 ％ in SCHB group (P-0.0025) and 0.13％ in MCHB group (P=0.0006),which were significantly higher than that in control group (0.03％),and the frequency of Tim-3 /PD-1-PBMC in the three groups were significantly lower than that in control group (P =0.0000),but the differences between HBsAg carriers (0.10％) and controls (0.03％) were not statistically significant (P=0.28).Among 160 subjects,78 were HLA-A2 positive.The frequency of Tim-3+/PD-1+ HBV-specific CD8+ T cells was 68.72％±17.21％ in ACLF group,and 59.66％± 19.25％ in SCHB group,which were significantly higher than that in HBsAg carrier group (33.93％ ± 10.80％,P=0.0000,P=0.0054).The frequency of Tim-3 /PD-1-HBV-specific CD8+ T cells in ACLF group was 2.80％,which was significantly lower than that in HBsAg carrier group (27.24％,P=0.0004).The frequency of Tim3+/PD-1+ HBV-specific CD8+ T cells was positively correlated with alanine aminotransferase (r=0.26,P=0.022),aspartate aminotransferase (r=0.28,P=0.012) and total bilirubin levels (r=0.36,P=0.001); and inversely correlated with albumin level (r=-0.35,P=0.002) in serum.Furthermore,it was positively correlated with international normalized ratio (INR,r=0.34,P =0.045) and model for end-stage liver disease score (r=0.43,P=0.027) in ACLF group.Conclusions Co-expressions of Tim-3 and PD-1 on PBMC and HBV-specific CD8+ T cells are significantly upregulated in patients with CHB,and correlated with liver inflammatory activities.These findings indicate that Tim-3 and PD-1 co-expression may involve in disease activity and liver failure in CHB.

Clinical significance of tissue inhibitor of metalloproteinases-1 in livers of patients with chronic hepatitis B

The Expression of TIMP-2 in Liver Tissues of Patients with Chronic Hepatitis B

Clinical Significance and Serum Level of TIMP-1 in Patients with Chronic Virus Hepatitis

Use of tissue inhibitors of metalloproteinase-1 (TIMP-1) as non-invasive diagnostic marker in hepatic fibrosis of chronic viral hepatitis

Relationships Between the TIMP-1,TIMP-2 and the Level of HA,PCIII,CIV and LN in the Serum of Patients with HBV Infected

Serum CHI3L1 As a Biomarker for Non-invasive Diagnosis of Liver Fibrosis.

The serum level of TIMP-2 in diagnosing hepatic fibrosis in patients with hepatitis B viral infection

Diagnostic Value of Platelet Derived Growth Factor-Bb, Transforming Growth Factor-Beta 1, Matrix Metalloproteinase-1, and Tissue Inhibitor of Matrix Metalloproteinase-1 in Serum and Peripheral Blood Mononuclear Cells for Hepatic Fibrosis

Relationship Between Expression Level of TIMP-3 and Invasion/metastasis of Hepatocellular Carcinoma

Circulating Matrix Metalloproteinases 1, 2, 9 and Their Inhibitors TIMP-1 and TIMP-2 as Serum Markers of Liver Fibrosis in Patients With Chronic Hepatitis C: Comparison With PIIINP and Hyaluronic Acid

The Expression of MMP - 1 and TIMP - 1 in Peripheral Mononucleocytes of Patients with Chronic Hepatitis

[The Diagnostic Value of Eight Serum Indices for Liver Fibrosis].

Significance of the serum level of transforming growth factor β1 and its difference in patients with chronic hepatitis B and HBV-induced hepatic cirrhosis

Tissue inhibitor of metalloproteinases-1 promotes liver fibrosis development in a transgenic mouse model

Correlation between programmed death-1 and T-cell immunoglobulin mucin-3 co-expression on hepatitis B virus-specific CD8+ T cells and liver inflammatory activities in patients with chronic hepatitis B virus infection

Expression Changes of Tim-3 As One of Supplementary Indicators for Monitoring Prognosis of Liver Pathological Changes in Chronic HBV Infection

Effects of Antisense Tissue Imhibitor of Metalloproteinase-1 Expressing Plasmid on Porcine Serum-Induced Rat Liver Fibrosis

Tissue inhibitors of metalloproteinases, hepatic stellate cells and liver fibrosis

Matrix Metallo-proteinase Inhibitor-1 and Hepatic Fibrosis

Effect of Interleukin-10 and Platelet-Derived Growth Factor on Expressions of Matrix Metalloproteinases-2 and Tissue Inhibitor of Metalloproteinases-1 in Rat Fibrotic Liver and Cultured Hepatic Stellate Cells

Correlation Analysis of IGF-2 and IGFBP-2 with MMPs in Patients with Liver Fibrosis